Epithelial to mesenchymal transition and M2 macrophages drive aggressiveness in murine and human sarcomatoid urothelial carcinoma.
This study characterizes novel murine bladder cancer cell lines, particularly the BBN966 sarcomatoid urothelial carcinoma (SUC) model, which recapitulates human SUC's aggressive EMT-driven biology and M2 macrophage infiltration, thereby providing a valuable preclinical platform for testing immunotherapies like anti-PD1.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Bladder cancer is not a single disease but a collection of different types, each behaving in its own way. Most cases follow a predictable pattern, responding well to standard treatments. However, a rare and dangerous variant known as sarcomatoid urothelial carcinoma behaves differently. It is aggressive, grows quickly, and often resists the therapies that work for other patients. Because this specific type is so uncommon, scientists have struggled to find enough samples to study it in the lab. Without a reliable model to test new drugs, developing better treatments has been like trying to navigate a dark room without a light. The central challenge has been creating a living system that mimics this rare human disease closely enough to be useful, yet is robust enough to grow in a laboratory setting where researchers can observe how it reacts to new ideas.
To solve this, a team of researchers at Johns Hopkins University and other institutions set out to build a new kind of model using mice. They started with bladder tumors that had been induced in mice using a chemical known to cause cancer. Initially, when they tried to grow these tumor cells in healthy mice with a full immune system, the cells simply refused to grow. The mice's natural defenses recognized the cells as foreign and stopped them from taking hold. The researchers then took a different approach. They moved the cells into mice that lacked mature immune systems, specifically those missing B and T cells, which are the body's primary soldiers against infection and cancer. In these immune-deficient mice, the tumor cells began to grow vigorously.
The team then performed a crucial step: they took the growing tumors from the immune-deficient mice and transferred them back into healthy mice with full immune systems. Surprisingly, the cells that had grown in the immune-deficient environment had changed. They had learned to survive and thrive even when facing a fully functional immune system. This process, which the researchers called "recycling," produced three distinct lines of tumor cells. Each line grew at a different speed and looked different under a microscope. Three independent experts in bladder pathology examined these new tumors and confirmed that they represented different types of the disease. One line, named BBN966, looked exactly like the aggressive sarcomatoid variant found in humans. Another, BBN964, appeared to be a mix between sarcomatoid and another type called squamous. The third, BBN975, resembled the squamous type.
The researchers then asked whether these new mouse models truly reflected the human disease. They looked at the genetic makeup of the tumors, comparing the mouse cells to data from human patients and even from dogs, which can develop similar bladder cancers. They found a striking consistency. The mouse tumor that looked like human sarcomatoid cancer, BBN966, shared a specific genetic signature with its human and canine counterparts. It lacked certain markers that are usually present in normal bladder cells, a trait known as a "double-negative" phenotype. It also showed high levels of a biological process called epithelial-to-mesenchymal transition, or EMT. In simple terms, EMT is when cells lose their ability to stick together and become more mobile, a change that allows cancer to spread. This same high level of EMT was found in the human and dog tumors, confirming that the mouse model had captured a key feature of the real disease.
The study also uncovered what was happening inside the tumor's environment, known as the tumor microenvironment. The researchers discovered that the aggressive BBN966 tumors were filled with a specific type of immune cell called an M2 macrophage. These cells are generally suppressive; they tend to calm down the immune system rather than attack the cancer. This finding matched what the team saw in human patients, where the most dangerous tumors were also rich in these suppressive cells. In contrast, the less aggressive hybrid tumor, BBN964, had a different mix of immune cells. This suggested that the way the immune system interacts with the tumor is a major factor in how aggressive the cancer becomes.
Finally, the team tested whether these new models could help predict how patients might respond to treatment. They focused on a class of drugs called immune checkpoint inhibitors, which work by taking the brakes off the immune system so it can attack the cancer. In human patients with sarcomatoid cancer, these drugs have shown promise, but not for everyone. The researchers measured a protein called PD-L1 on the surface of human tumors and found that more than half of the patients had very high levels of this protein, which often signals that the tumor might respond to these drugs. When they treated the BBN966 mouse tumors with an antibody that blocks the same pathway, the tumors grew significantly slower. The hybrid BBN964 tumors, however, showed a mixed response, with some shrinking and others continuing to grow. This result mirrored the variability seen in human patients, suggesting that the mouse model could be used to test which combinations of drugs might work best for different types of this difficult cancer.
By creating these three distinct, growing models, the researchers have provided a new tool for the scientific community. They have shown that it is possible to generate tumors that mimic the rare, aggressive forms of bladder cancer found in people. These models are not just copies; they carry the same genetic and immune characteristics that make the human disease so hard to treat. With these tools, scientists can now test new therapies in a living system that behaves like the real thing, offering a clearer path toward finding effective treatments for patients who currently have very few options.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.